[Clinical outcomes of allogeneic hematopoietic stem cell transplantation for adult primary myelofibrosis: retrospective analysis by Fukuoka BMT group].

Tomohiko Kamimura, Chong Yong, Yoshikiyo Ito, Hideho Henzan, Toshihiro Miyamoto, Yusyu Ohno, Tetsuya Eto, Katsuto Takenaka, Koichi Akashi

Research output: Contribution to journalReview article

Abstract

We retrospectively analyzed outcomes of eight evaluable patients with primary myelofibrosis (PMF) who received allogeneic hematopoietic stem cell transplantation (allo-HSCT), using different graft sources; four patients received peripheral blood stem cells, three bone marrow, and one umbilical cord blood. The median age was 48 years (range, 43~64 years). Seven patients had an intermediate or high Dupriez score. Three patients underwent myeloablative conditioning, whereas five underwent reduced-intensity conditioning regimens. Engraftment was obtained in all of these recipients. The median days to reach a neutrophil count above 0.5×10(9)/l and platelet count above 20×10(9)/l were 20 and 35 days, respectively. No treatment-related deaths were observed within 100 days after allo-HSCT. Two patients died of sepsis or late-onset non-infectious pulmonary complications. Four patients developed grade I to II acute GVHD, and six patients developed chronic GVHD. The estimated 3-year overall survival was 75% with a median follow up time of 43 months (range, 6~127). Four of 5 patients who were transfusion-dependent became free from transfusion after allo-HSCT. In six of seven patients, a regression of fibrosis was confirmed by bone marrow biopsy. Despite the small number of cases, our results suggested that allo-HSCT is an encouraging curative strategy for treating PMF.

Original languageEnglish
Pages (from-to)323-328
Number of pages6
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume53
Issue number3
Publication statusPublished - Jan 1 2012

Fingerprint

Primary Myelofibrosis
Hematopoietic Stem Cell Transplantation
Bone Marrow
Platelet Count
Fetal Blood
Sepsis
Neutrophils
Fibrosis
Transplants
Biopsy
Lung
Survival

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

[Clinical outcomes of allogeneic hematopoietic stem cell transplantation for adult primary myelofibrosis : retrospective analysis by Fukuoka BMT group]. / Kamimura, Tomohiko; Yong, Chong; Ito, Yoshikiyo; Henzan, Hideho; Miyamoto, Toshihiro; Ohno, Yusyu; Eto, Tetsuya; Takenaka, Katsuto; Akashi, Koichi.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 53, No. 3, 01.01.2012, p. 323-328.

Research output: Contribution to journalReview article

@article{7777eb6632094042a7a4aedab766943a,
title = "[Clinical outcomes of allogeneic hematopoietic stem cell transplantation for adult primary myelofibrosis: retrospective analysis by Fukuoka BMT group].",
abstract = "We retrospectively analyzed outcomes of eight evaluable patients with primary myelofibrosis (PMF) who received allogeneic hematopoietic stem cell transplantation (allo-HSCT), using different graft sources; four patients received peripheral blood stem cells, three bone marrow, and one umbilical cord blood. The median age was 48 years (range, 43~64 years). Seven patients had an intermediate or high Dupriez score. Three patients underwent myeloablative conditioning, whereas five underwent reduced-intensity conditioning regimens. Engraftment was obtained in all of these recipients. The median days to reach a neutrophil count above 0.5×10(9)/l and platelet count above 20×10(9)/l were 20 and 35 days, respectively. No treatment-related deaths were observed within 100 days after allo-HSCT. Two patients died of sepsis or late-onset non-infectious pulmonary complications. Four patients developed grade I to II acute GVHD, and six patients developed chronic GVHD. The estimated 3-year overall survival was 75{\%} with a median follow up time of 43 months (range, 6~127). Four of 5 patients who were transfusion-dependent became free from transfusion after allo-HSCT. In six of seven patients, a regression of fibrosis was confirmed by bone marrow biopsy. Despite the small number of cases, our results suggested that allo-HSCT is an encouraging curative strategy for treating PMF.",
author = "Tomohiko Kamimura and Chong Yong and Yoshikiyo Ito and Hideho Henzan and Toshihiro Miyamoto and Yusyu Ohno and Tetsuya Eto and Katsuto Takenaka and Koichi Akashi",
year = "2012",
month = "1",
day = "1",
language = "English",
volume = "53",
pages = "323--328",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "3",

}

TY - JOUR

T1 - [Clinical outcomes of allogeneic hematopoietic stem cell transplantation for adult primary myelofibrosis

T2 - retrospective analysis by Fukuoka BMT group].

AU - Kamimura, Tomohiko

AU - Yong, Chong

AU - Ito, Yoshikiyo

AU - Henzan, Hideho

AU - Miyamoto, Toshihiro

AU - Ohno, Yusyu

AU - Eto, Tetsuya

AU - Takenaka, Katsuto

AU - Akashi, Koichi

PY - 2012/1/1

Y1 - 2012/1/1

N2 - We retrospectively analyzed outcomes of eight evaluable patients with primary myelofibrosis (PMF) who received allogeneic hematopoietic stem cell transplantation (allo-HSCT), using different graft sources; four patients received peripheral blood stem cells, three bone marrow, and one umbilical cord blood. The median age was 48 years (range, 43~64 years). Seven patients had an intermediate or high Dupriez score. Three patients underwent myeloablative conditioning, whereas five underwent reduced-intensity conditioning regimens. Engraftment was obtained in all of these recipients. The median days to reach a neutrophil count above 0.5×10(9)/l and platelet count above 20×10(9)/l were 20 and 35 days, respectively. No treatment-related deaths were observed within 100 days after allo-HSCT. Two patients died of sepsis or late-onset non-infectious pulmonary complications. Four patients developed grade I to II acute GVHD, and six patients developed chronic GVHD. The estimated 3-year overall survival was 75% with a median follow up time of 43 months (range, 6~127). Four of 5 patients who were transfusion-dependent became free from transfusion after allo-HSCT. In six of seven patients, a regression of fibrosis was confirmed by bone marrow biopsy. Despite the small number of cases, our results suggested that allo-HSCT is an encouraging curative strategy for treating PMF.

AB - We retrospectively analyzed outcomes of eight evaluable patients with primary myelofibrosis (PMF) who received allogeneic hematopoietic stem cell transplantation (allo-HSCT), using different graft sources; four patients received peripheral blood stem cells, three bone marrow, and one umbilical cord blood. The median age was 48 years (range, 43~64 years). Seven patients had an intermediate or high Dupriez score. Three patients underwent myeloablative conditioning, whereas five underwent reduced-intensity conditioning regimens. Engraftment was obtained in all of these recipients. The median days to reach a neutrophil count above 0.5×10(9)/l and platelet count above 20×10(9)/l were 20 and 35 days, respectively. No treatment-related deaths were observed within 100 days after allo-HSCT. Two patients died of sepsis or late-onset non-infectious pulmonary complications. Four patients developed grade I to II acute GVHD, and six patients developed chronic GVHD. The estimated 3-year overall survival was 75% with a median follow up time of 43 months (range, 6~127). Four of 5 patients who were transfusion-dependent became free from transfusion after allo-HSCT. In six of seven patients, a regression of fibrosis was confirmed by bone marrow biopsy. Despite the small number of cases, our results suggested that allo-HSCT is an encouraging curative strategy for treating PMF.

UR - http://www.scopus.com/inward/record.url?scp=84871690384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871690384&partnerID=8YFLogxK

M3 - Review article

C2 - 22499049

AN - SCOPUS:84871690384

VL - 53

SP - 323

EP - 328

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 3

ER -